26 results
ARS
2024 FY
CCCC
C4 Therapeutics Inc
30 Apr 24
Annual report to shareholders
8:52am
business decisions entered into by drug innovators as a way to address risk and that these settlements should, therefore, be immune from antitrust attack … ; and (e) that antitrust liability for large unjustified payments does not prevent litigating parties from settling their lawsuits, for example, by allowing
ARS
hwmkuv
28 Apr 23
Annual report to shareholders
7:03am
424B4
9xn 1s8qasfwkv
21 Jun 21
Prospectus supplement with pricing info
8:08am
DRS
m84ifq8xbmddo6 hwq2
19 May 21
Draft registration statement
12:00am
10-K
dkb0su4bcjgesigvk3
11 Mar 21
Annual report
4:19pm
10-Q
6mz0zofoo0c7k5xn
12 Nov 20
Quarterly report
4:28pm